Walvax Biotechnology Co., Ltd. (SHE:300142)

Walvax Biotechnology Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020
Operating Revenue	2,666	2,804	4,106	5,079	3,452	2,927
Other Revenue	17.86	17.86	7.92	7.65	10.5	11.62
Revenue	2,684	2,821	4,114	5,086	3,463	2,939
Revenue Growth (YoY)	-30.83%	-31.41%	-19.12%	46.89%	17.82%	162.13%
Cost of Revenue	758.78	740.48	749.39	673.14	403.54	404.53
Gross Profit	1,925	2,081	3,364	4,413	3,059	2,534
Selling, General & Admin	1,363	1,400	1,817	2,302	1,636	1,352
Research & Development	576.43	596.54	776.43	922.25	616.36	173.78
Other Operating Expenses	13.45	-4.12	-100	16.48	19.83	-8.34
Operating Expenses	2,025	2,057	2,533	3,239	2,267	1,511
Operating Income	-100.1	24.01	831.05	1,174	792.22	1,024
Interest Expense	-5.45	-8.43	-5.95	-7.11	-5.77	-0.6
Interest & Investment Income	59	66.75	81.35	81.82	103.29	42.83
Currency Exchange Gain (Loss)	4.05	4.05	3.06	0.82	-0.22	-4.65
Other Non Operating Income (Expenses)	82.87	80.95	-63.64	-75.39	33.88	39.57
EBT Excluding Unusual Items	40.16	167.33	845.86	1,174	923.4	1,101
Gain (Loss) on Sale of Investments	0.62	-98.34	-234.75	-199.33	-280.74	279.89
Gain (Loss) on Sale of Assets	-1.74	-1.77	-0.83	-0.38	0.23	-1.08
Asset Writedown	-52.12	-7.68	-11.31	-1.66	-5.11	-6.6
Other Unusual Items	125.57	124.96	-	97.8	71.15	-
Pretax Income	112.48	184.5	598.98	1,070	708.95	1,373
Income Tax Expense	-3.92	10.1	87.65	132.24	107.59	162.12
Earnings From Continuing Operations	116.4	174.4	511.33	938.23	601.35	1,211
Net Income to Company	116.4	174.4	511.33	938.23	601.35	1,211
Minority Interest in Earnings	14.28	-32.24	-91.93	-209.57	-173.6	-208
Net Income	130.68	142.16	419.39	728.65	427.75	1,003
Net Income to Common	130.68	142.16	419.39	728.65	427.75	1,003
Net Income Growth	-50.03%	-66.10%	-42.44%	70.35%	-57.36%	606.60%
Shares Outstanding (Basic)	1,587	1,599	1,600	1,603	1,569	1,539
Shares Outstanding (Diluted)	1,587	1,599	1,600	1,604	1,573	1,559
Shares Change (YoY)	-0.89%	-0.06%	-0.21%	1.93%	0.90%	1.37%
EPS (Basic)	0.08	0.09	0.26	0.45	0.27	0.65
EPS (Diluted)	0.08	0.09	0.26	0.45	0.27	0.64
EPS Growth	-49.59%	-66.08%	-42.32%	67.12%	-57.74%	597.07%
Free Cash Flow	483.52	486.49	188.25	110.31	-398.21	-292.94
Free Cash Flow Per Share	0.30	0.30	0.12	0.07	-0.25	-0.19
Dividend Per Share	0.010	0.010	0.010	0.010	0.027	0.070
Dividend Growth	-	-	-	-62.96%	-61.43%	-
Gross Margin	71.73%	73.76%	81.78%	86.77%	88.35%	86.24%
Operating Margin	-3.73%	0.85%	20.20%	23.08%	22.88%	34.84%
Profit Margin	4.87%	5.04%	10.20%	14.32%	12.35%	34.13%
Free Cash Flow Margin	18.02%	17.24%	4.58%	2.17%	-11.50%	-9.97%
EBITDA	281.89	387.61	1,121	1,422	927.65	1,148
EBITDA Margin	10.50%	13.74%	27.25%	27.96%	26.79%	39.06%
D&A For EBITDA	382	363.59	289.97	248.4	135.43	123.95
EBIT	-100.1	24.01	831.05	1,174	792.22	1,024
EBIT Margin	-3.73%	0.85%	20.20%	23.08%	22.88%	34.84%
Effective Tax Rate	-	5.48%	14.63%	12.35%	15.18%	11.80%
Revenue as Reported	2,684	2,821	4,114	5,086	-	-
Advertising Expenses	-	42.66	78.01	94.83	24.15	20.85

Source: S&P Global Market Intelligence. Standard template. Financial Sources.